Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.

Ansari, M; Sauty, G; Labuda, M; Gagné, V; Rousseau, J; Moghrabi, A; Laverdière, C; Sinnett, D; Krajinovic, M

Ansari, M; Sauty, G; Labuda, M; Gagné, V; Rousseau, J; Moghrabi, A; Laverdière, C; Sinnett, D; Krajinovic, M.

Affiliation

Ansari M; Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada.

Pharmacogenomics J ; 12(5): 386-94, 2012 Oct.

Article in En | MEDLINE | ID: mdl-21606946

Subject(s)

Biomarkers, Pharmacological; Methotrexate/therapeutic use; Multidrug Resistance-Associated Proteins/genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy; Alleles; Disease-Free Survival; Genetic Association Studies; Genotype; Haplotypes; Humans; Multidrug Resistance-Associated Proteins/metabolism; Polymorphism, Single Nucleotide/genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Methotrexate / Multidrug Resistance-Associated Proteins / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Biomarkers, Pharmacological Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Pharmacogenomics J Journal subject: BIOLOGIA MOLECULAR / FARMACOLOGIA Year: 2012 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google